Vaccine developer Vaxcyte has floated in an upsized initial public offering having raised $110m in a Roche-backed round just three months ago.
Pharmaceutical firm Roche has scored an exit after US-based vaccine developer Vaxcyte floated on the Nasdaq Global Select Market in a $250m initial public offering.
The company priced more than 15.6 million shares at $16.00 each having previously set a range of $14 to $16 for 14 million shares. It floated on Friday and its shares had risen to $28.52 at close of trading yesterday.
Formerly known as SutroVax, Vaxcyte was spun off by biopharmaceutical company Sutro Biopharma and…
